DDInter1925 DDInter1435
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Vemurafenib {u} (Compound) resembles {v} (Compound) Etoricoxib
Vemurafenib {u} (Compound) treats {v} (Disease) skin cancer
Vemurafenib {u} (Compound) binds {v} (Gene) CYP3A4
Vemurafenib {u} (Compound) upregulates {v} (Gene) DHRS12
Vemurafenib {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Vemurafenib {u} (Compound) downregulates {v} (Gene) CLPP
Vemurafenib {u} (Compound) causes {v} (Side Effect) Eosinophilia
Vemurafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Vemurafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ambrisentan
Vemurafenib (Compound) resembles Etoricoxib (Compound)
Vemurafenib (Compound) treats skin cancer (Disease)
Vemurafenib (Compound) binds CYP3A4 (Gene)
Vemurafenib (Compound) upregulates DHRS12 (Gene)
Vemurafenib (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Vemurafenib (Compound) downregulates CLPP (Gene)
Vemurafenib (Compound) causes Eosinophilia (Side Effect)
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ambrisentan